-
Tianjin Cancer Hospital hosted the first overseas venue for ASCO breast cancer in China.
Time of Update: 2020-08-14
executive chairman of the conference, Vice Chairman of the Breast Cancer Professional Committee of the China Anti-Cancer Association, Professor Zhang Wei, Director of the Breast Oncology Department of Tianjin Cancer Hospital, said that the number and growth rate of breast cancer in China are among the highest in the world, with an average five-year disease-free survival rate nearly 10% lower than in the United States.
-
Strong join forces! Roche and Dean's diagnosis have partnered with tumor gene sequencing.
Time of Update: 2020-08-14
On April 27, Roche, an internationally renowned pharmaceutical company, announced that Roche and its holding company Foundation Medicine had signed a technical authorization agreement with Dean Diagnostics for Comprehensive Genomic Sequencing Analysis (CGP).
Dean Diagnostics is expected to launch two more analytical molecular information products in 2019® FoundationOne ® Heme and Foundation ACT ® .
-
China's start-up gene detection technology to help the tumor precision treatment research.
Time of Update: 2020-08-14
(Health Times reporter Mao Yuanyuan) Recently, at the 14th National Conference on Colorectal Cancer, the China Anti-Cancer Association Colorectal Cancer Professional Committee launched a ctDNA test to
-
Health Committee: 5-year survival rate of malignant tumors has been raised to 40.5%
Time of Update: 2020-08-14
On June 8, the National Health And Wellness Board held a special press conference to introduce China's upgrading of medical technical capabilities and medical quality management level. According to t
-
FDA approves first new treatment for rare adrenal tumors!
Time of Update: 2020-08-14
But patients still lack effective systemic therapies for symptoms such as tumor-related hypertension, and now they have an approved treatment that can be used to lower their blood pressure and reduce the size of tumors in some patients.
-
First! FDA approves rare adrenal tumor therapy.
Time of Update: 2020-08-14
Recently, the U.S. Food and Drug Administration (FDA) approved Azedra (IOBEGUUNI I 131) for the treatment of rare adrenal tumors that cannot be surgically removed and require systemic anti-cancer treatment, mainly for adults and adolescents 12 years of age and older.
-
Radiotherapy department, more than 70% of cancer patients need radiation therapy!
Time of Update: 2020-08-14
(Health Times reporter Qi Wei) At present, malignant tumors seriously endanger human health. Because of the general late ness of cancer in China, the mortality rate is higher than the global average,
-
Tumor clouds! The "invisible knife" of the completed tumor has to look at minimally invasive intervention.
Time of Update: 2020-08-14
(Health Times reporter Huang Lanjun) If the surgical knife in the tumor treatment can decay into magic, that includes radio frequency ablation, including minimally invasive intervention, should be cou
-
Cancer patients are a boon! Baiyang hand-in-hand medicine, tumor radiotherapy to have a big action!
Time of Update: 2020-08-14
(Health Times reporter Zhang He) recently, Baiyang Pharmaceutical Group's Baiyang Intelligent Technology and Medical University jointly announced that the two sides signed a strategic cooperation agreement to jointly promote the use of medical artificial intelligence in the field of tumor treatment, to provide patients with personalized, standardized treatment options.
-
Shanghai Cancer Hospital: Professor Ye Dingwei's personal primary knife prostate cancer treatment surgery broke 3000 cases.
Time of Update: 2020-08-14
in recent years, the urology department of Fudan University Affiliated Oncology Hospital has taken the lead in using Internet technology and artificial intelligence technology to improve the construction of "two platforms" - the first full-time management online platform covering urinary and male reproductive system tumor patients in China, the first cross-regional urinary tumor MDT online consultation platform.
-
FDA approves new treatment for gastrointestinal pancreatic neuroendocrine tumors.
Time of Update: 2020-08-14
Recently, the U.S. Food and Drug Administration (FDA) approved Lutathera (l Lu 177 dotatate) for the treatment of gastrointestinal pancreatic neuroendocrine tumors (GEP-NETs).
It's worth noting that the second clinical trial recruited patients as part of the FDA's Expanded Use program, which allows patients with serious, life-threatening diseases to be treated with new drugs.
-
"Mini" liver tumors are manufactured in the laboratory for the first time.
Time of Update: 2020-08-14
The researchers say the micro-tumor model could be used to screen new liver cancer drugs, reduce the number of experimental animals, and even develop personalized therapies for liver cancer patients in the future.
-
Anti-tumor new drug diphatopyl pyreth in the United States approved clinical!
Time of Update: 2020-08-14
xylene sulfonate protinib is the first target anti-small cell lung cancer drug in China for the absence of eGFR19 exoon, no.
The announcement indicates that the company has independent intellectual property rights over xylene sulfonate poutini and tablets, and no identical products are currently available in China.
-
Two new therapeutic drugs for blood tumors are on the market in China!
Time of Update: 2020-08-14
Following the "priority review" of the Drug Review Center of the State Food and Drug Administration in December last year, ibtinib capsules were approved by the State Food and Drug Administration on August 24 this year and were officially launched 69 days after approval, providing an important new treatment option for long-awaited Chinese patients.
-
Oncology Hospital Director: Family has cancer don't hide.
Time of Update: 2020-08-14
"This also reflects the high level of cancer diagnosis and treatment in Zhejiang Province, tumor patients have been better diagnosed and treated." tumor is a kind of "old age", "chronic disease", so, to face it with the right attitude, do not have to "talk about cancer color change", also should not completely hide the patient's condition.
-
China's first PD-1 antibody drug approved! China has entered the era of cancer immunity.
Time of Update: 2020-08-14
"PD-1 antibody drugs were approved for market", on June 15, the State Drug Administration's official website hung a message to the pharmaceutical industry boiling up, China officially approved the Navuliu single anti-injection injection registration application.
-
The first eye disease eye tumor alliance was established in China.
Time of Update: 2020-08-14
(Health Times reporter Yan Wei Shanghai Nine Hospital Xu Ying) by the Shanghai Jiaotong University School of Medicine affiliated with the Ninth People's Hospital led by the establishment of the countr
-
8 big new drugs on the market this year! Tumors, diabetes, eye disease... The patient's gospel.
Time of Update: 2020-08-14
(Health Times reporter Yang Yue ) 2018, a large wave of imported and domestic new drugs through the priority review channel was approved for listing. This year is not only imported drugs, domestic in
-
Electroacupuncture accelerates postoperative recovery of tumors by Chinese and foreign experts praise!
Time of Update: 2020-08-14
Director Wang Chengfeng of pancreatic gastric surgery and Chinese and foreign experts made a preliminary discussion on the future of scientific research and clinical cooperation, personnel training, personnel exchanges and other matters.
-
New advances in cancer hunger therapy! Shanghai Cancer Therapy is published in the journal Nature.
Time of Update: 2020-08-13
recently, the cooperation team of Professor Pawenbo of the School of Chemistry and Molecular Engineering of East China Normal University and Shi Jianlin Researcher of the Shanghai Silicate Research Institute of the Chinese Academy of Sciences successfully prepared a single-dispersed, mg2Si-nano-oxygen-consuming agent with a single dispersion, about 100 nm diameter, and a stable solution after surface modification of polyethylene pyrethroid (PVP) to give it a good injection.
